Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,415.16 41.46 +3.02%
Market cap
$1.29T
P/E
47.5×
Fwd P/E
36.7×
Dividend yield
0.47%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100

Eli Lilly and Company (LLY) EV/FCF

Alert me on EV/FCF

As of 30 October 2026, Eli Lilly and Company (LLY) trades at a EV/FCF of 64.2×. Over the past ten years it has ranged from 16.2× (February 2018) to 534× (June 2024); the current reading is higher than 74% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 89.5× (26.10%)
FY2024 121× (45.88%)
FY2023 224× 277.89%
FY2022 59.2× 45.26%
FY2021 40.8× 35.42%
FY2020 30.1× (6.35%)
FY2019 32.1× 25.74%
FY2018 25.6× 38.98%
FY2017 18.4× (2.79%)
FY2016 18.9× (51.17%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 54.7× (10.57%)
Mar 2026 61.2× (31.58%)
Dec 2025 89.5× 42.35%
Sep 2025 62.8× (39.52%)
42 more quarters

Against its own ten years

Low 16.2× High 534×
Ten-year median 36.3×
Current reading's percentile 71

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on LLY